Gilteritinib

Last Updated: 06/30/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 544 publications

P300/CBP inhibition with inobrodib in combination with gilteritinib and venetoclax targets leukemia stem cells in epigenetic mutant AML.

P300/CBP inhibition with inobrodib in combination with gilteritinib and venetoclax targets leukemia stem cells in epigenetic mutant AML.

Journal: Science advances
Published: May 15, 2026

Corrigendum to "Gilteritinib reverses ABCB1-mediated multidrug resistance: Preclinical in vitro and animal investigations" [Biomed. Pharmacother. 180 (2024) 117603].

Corrigendum to "Gilteritinib reverses ABCB1-mediated multidrug resistance: Preclinical in vitro and animal investigations" [Biomed. Pharmacother. 180 (2024) 117603].

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: May 06, 2026

Mechanistic Considerations and a Clinical Caveat Regarding the Cord-Blood-Specific Signal of Post-Hematopoietic Stem Cell Transplantation Gilteritinib Maintenance.

Mechanistic Considerations and a Clinical Caveat Regarding the Cord-Blood-Specific Signal of Post-Hematopoietic Stem Cell Transplantation Gilteritinib Maintenance.

Journal: Transplantation and cellular therapy
Published: April 30, 2026

Targeting FLT-3 Mutations in Acute Myeloid Leukaemia: from Molecular Insights to Clinical Strategies.

Targeting FLT-3 Mutations in Acute Myeloid Leukaemia: from Molecular Insights to Clinical Strategies.

Journal: Folia biologica
Published: April 14, 2026

Myeloid/lymphoid neoplasm with FLT3 gene fusion: report of a case with a novel t(5;13)(q13;q12) SSBP2::FLT3 fusion.

Myeloid/lymphoid neoplasm with FLT3 gene fusion: report of a case with a novel t(5;13)(q13;q12) SSBP2::FLT3 fusion.

Journal: Journal of hematopathology
Published: April 02, 2026

Clinicopathological Challenge: A Rapidly Progressive Bullous Ulcer in a Patient Receiving Gilteritinib.

Clinicopathological Challenge: A Rapidly Progressive Bullous Ulcer in a Patient Receiving Gilteritinib.

Journal: International journal of dermatology
Published: March 17, 2026

Efficacy and safety of FLT3 inhibitors for acute myeloid leukemia: a network meta-analysis.

Efficacy and safety of FLT3 inhibitors for acute myeloid leukemia: a network meta-analysis.

Journal: Frontiers in oncology
Published: March 16, 2026

Venetoclax plus azacitidine as successful bridging therapy to second transplantation for post-transplant extramedullary relapse of acute myeloid leukemia

Venetoclax plus azacitidine as successful bridging therapy to second transplantation for post-transplant extramedullary relapse of acute myeloid leukemia

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: March 04, 2026

Gilteritinib + chemotherapy in children with relapsed/refractory FLT3-ITD AML: results from the phase 1/2 SKIPPER trial.

Gilteritinib + chemotherapy in children with relapsed/refractory FLT3-ITD AML: results from the phase 1/2 SKIPPER trial.

Journal: Blood advances
Published: February 19, 2026

Targeted Therapy in Acute Myeloid Leukemia: Current Approaches and Novel Directions.

Targeted Therapy in Acute Myeloid Leukemia: Current Approaches and Novel Directions.

Journal: Journal of personalized medicine
Published: February 16, 2026

Maintenance Treatment With Gilteritinib Suppresses Post-transplant Relapse in Relapse/Refractory FLT3-Mutated Acute Myeloid Leukemia.

Maintenance Treatment With Gilteritinib Suppresses Post-transplant Relapse in Relapse/Refractory FLT3-Mutated Acute Myeloid Leukemia.

Journal: Transplantation and cellular therapy
Published: February 14, 2026

The novel ALK K1150dup mutation mediates resistance to frontline lorlatinib and retains sensitivity to gilteritinib.

The novel ALK K1150dup mutation mediates resistance to frontline lorlatinib and retains sensitivity to gilteritinib.

Journal: NPJ precision oncology
Published: February 13, 2026
Showing 1-12 of 544

Last Updated: 06/30/2026